专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022189432A1 AN OLEOGEL COMPOSITION COMPRISING AN ETHYLCELLULOSE AND AN OILY ACTIVE INGREDIENT 审中-公开
公开(公告)号：WO2022189432A1
公开(公告)日：2022-09-15
申请号：PCT/EP2022/055894
申请日：2022-03-08
申请人： NUTRITION & BIOSCIENCES USA 1, LLC
发明人： PUTANS, Rebecca , ROGERS, True L. , SCHALAU, Gerald K. , O'DONNELL, Kevin K. P.
IPC分类号： A61K9/06 , A61K9/56
摘要： An oleogel composition comprises an ethylcellulose polymer, a first, non-volatile oil which is an active ingredient and a second oil selected from the group consisting of triglyceride oils and mineral oils.

2. 发明申请

WO2022160022A1 IMPLANTE SUBCUTÂNEO REABSORVÍVEL DE LONGA DURAÇÃO COM LIBERAÇÃO PROLONGADA DE SUBSTÂNCIA FARMACOLOGICAMENTE ATIVA PRÉ-CONCENTRADA EM POLÍMERO PARA TRATAMENTO DA DIABETES MELLITUS TIPO 2 E PROCESSO 审中-公开
公开(公告)号：WO2022160022A1
公开(公告)日：2022-08-04
申请号：PCT/BR2021/050061
申请日：2021-02-08
申请人： LUIZ PERACCHI, Edson
发明人： LUIZ PERACCHI, Edson
IPC分类号： A61K9/56 , A61K31/155 , A61K31/4985 , A61K31/4439 , A61K38/26 , A61P3/10
摘要： O privilégio de invenção é voltado ao setor de saúde e compreende um implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da diabetes mellitus tipo 2. O implante biodegradável é inserido por via subcutânea e possui liberação contínua do ativo por um período de tempo prolongado. O implante é preferencialmente formado por partículas do ativo dispersas homogeneamente em uma matriz polimérica bioerodível e bioabsorvível. Os implantes podem ter qualquer tamanho, forma ou estrutura que facilite a sua fabricação e inserção subcutânea, entretanto, para se obter uma liberação mais constante e uniforme do ativo é necessário utilizar formas geométricas que mantém sua área superficial ao longo do tempo.

3. 发明申请

WO2021073094A1 以原花色素为壁材的鱼油微胶囊及制备方法审中-公开
公开(公告)号：WO2021073094A1
公开(公告)日：2021-04-22
申请号：PCT/CN2020/091799
申请日：2020-05-22
申请人：浙江大学
发明人：叶兴乾 , 潘海波 , 陈士国 , 沈学敏 , 陈健初 , 刘东红
IPC分类号： A23D9/04 , A61K9/56 , A23L33/115 , A23P10/30
摘要：本发明公开了一种以原花色素为壁材的鱼油微胶囊，由以下重量含量的成分组成：5-10％的壁材和90-95％鱼油；所述壁材为杨梅叶原花色素，杨梅叶原花色素由杨梅叶制备而得。本发明还同时公开了上述鱼油做胶囊的制备方法。采用本发明方法制备的鱼油微胶囊质量稳定、存储性能好，能广泛地添加到各种食品中。

4. 发明申请

WO2015157138A1 ABUSE-DETERRENT CONTROLLED RELEASE FORMULATIONS 审中-公开
标题翻译：滥用控制释放公式
公开(公告)号：WO2015157138A1
公开(公告)日：2015-10-15
申请号：PCT/US2015/024422
申请日：2015-04-06
申请人： BANNER LIFE SCIENCES LLC
发明人： VAMVAKAS, George , FATMI, Aqeel
IPC分类号： A61K9/52 , A61K9/56 , A61K9/48 , A61K47/30 , A61K31/137
CPC分类号： A61K9/4866 , A61K9/485 , A61K9/4858 , A61K9/4875 , A61K31/137 , A61K31/485
摘要： Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharmaceutical ingredient are described.
摘要翻译：本文描述的是滥用威慑控制释放口服药物组合物及其制备方法。特别地，描述了包含软胶囊和包含活性药物成分的滥用威慑控制释放基质的滥用威慑控释药物组合物。

5. 发明申请

WO2006103661A2 CONTROLLED ABSORPTION OF STATINS IN THE INTESTINE 审中-公开
标题翻译：控制在INTESTINE中吸收统计数据
公开(公告)号：WO2006103661A2
公开(公告)日：2006-10-05
申请号：PCT/IL2006/000387
申请日：2006-03-27
申请人： DEXCEL PHARMA TECHNOLOGIES LTD. , PENHASI, Adel , RUDERMAN, Marina , GOMBERG, Maxim
发明人： PENHASI, Adel , RUDERMAN, Marina , GOMBERG, Maxim
IPC分类号： A61K9/56
CPC分类号： A61K31/00 , A61K9/2846 , A61K9/2866
摘要： A delayed onset controlled release formulation is provided in which controlled release of the active ingredient occurs preferentially in the lower gastrointestinal tract including the colon. The formulation supports a significantly higher bioavailability of the active ingredient in the body of the subject than can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core, over which an outer coating is layered. The core is optionally and preferably in the form of a tablet.
摘要翻译：提供延迟发作控制释放制剂，其中活性成分的控制释放优先在包括结肠的下胃肠道中。该制剂支持比目前使用的常规制剂可以实现的受试者体内活性成分显着更高的生物利用度，使得他汀在给药后长时间内维持治疗上显着的血浆水平。制剂优选具有芯，其上层叠有外涂层。芯可选地优选为片剂的形式。

6. 发明申请

WO2006079019A2 THERAPEUTIC PEPTIDE FORMULATIONS WITH IMPROVED STABILITY 审中-公开
标题翻译：具有改善稳定性的治疗肽制剂
公开(公告)号：WO2006079019A2
公开(公告)日：2006-07-27
申请号：PCT/US2006002262
申请日：2006-01-19
申请人： ALZA CORP , CORMIER MICHEL J N , AMERI MAHMOUD
发明人： CORMIER MICHEL J N , AMERI MAHMOUD
IPC分类号： A61K9/19 , A61K9/56 , A61K38/00
CPC分类号： A61K9/0021 , A61K38/25 , A61K47/02 , A61K47/12 , A61M37/0015 , A61M2037/0046 , A61M2037/0061
摘要： Compositions of and methods for formulating and delivering peptide, polypeptide and protein therapeutic agent formulations having enhanced physical stability, and wherein fibril formation is minimized and/or controlled, to yield a consistent and predictable composition viscosity. The compositions of and methods for formulating and delivering peptide, polypeptide and protein therapeutic agents of the present invention further facilitate their incorporation into a biocompatible coating which can be employed to coat a stratum-corneum piercing microprojection, or a plurality of stratum-corneum piercing microprojections of a delivery device, for delivery of the biocompatible coating through the skin of a subject, thus providing an effective means of delivering the peptide therapeutic agents.
摘要翻译：用于配制和递送具有增强的物理稳定性的肽，多肽和蛋白质治疗剂制剂的组合物和方法，并且其中原纤维形成被最小化和/或控制以产生一致且可预测的组合物粘度。用于配制和递送本发明的肽，多肽和蛋白质治疗剂的组合物和方法进一步促进它们掺入生物相容性涂层中，所述生物相容性涂层可用于涂覆角质层刺穿的微突出物或多个角质层刺穿的微突起的递送装置，用于通过受试者的皮肤递送生物相容性涂层，从而提供递送肽治疗剂的有效手段。

7. 发明申请

WO2005055955A3 DOSING METHODS FOR ß-D-2',3'-DIDEOXY-2',3'-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY 审中-公开
标题翻译： ß-D-2'，3'-二脱氧-2'，3'-二脱氢-5-氟尿嘧啶抗病毒治疗方法
公开(公告)号：WO2005055955A3
公开(公告)日：2006-03-30
申请号：PCT/US2004041503
申请日：2004-12-09
申请人： PHARMASSET INC , INCYTE CORP , OTTO MICHAEL J , ROSA ABEL DE LA , YELESWARAM KRISHNASWAMY
发明人： OTTO MICHAEL J , ROSA ABEL DE LA , YELESWARAM KRISHNASWAMY
IPC分类号： A61K9/14 , A61K20060101 , A61K9/16 , A61K9/20 , A61K9/24 , A61K9/28 , A61K9/48 , A61K9/50 , A61K9/56 , A61K31/70 , A61K31/7072
CPC分类号： A61K9/2846 , A61K9/2077 , A61K9/2866 , A61K9/2886 , A61K9/5026 , A61K9/5078 , A61K31/7072
摘要： The disclosed invention is a composition for and a method of treating a HIV infection in a host, such as a human, using a single, once a day, oral dose of ß-D-D4FC in an enteric-coated tablet. The enterically coated ß-D-D4FC increases the amount of the drug that remains in active form for use in inhibiting the HIV virus
摘要翻译：所公开的发明是在肠溶衣片剂中使用单次一次一次口服剂量的β-D-D4FC来治疗宿主例如人的HIV感染的组合物和方法。肠溶包衣的β-D-D4FC增加了用于抑制HIV病毒的活性形式的药物的量

8. 发明申请

WO2004014322A3 IMMUNOMODULATORY COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF 审中-公开
标题翻译：免疫调节组合物，制备方法和使用方法
公开(公告)号：WO2004014322A3
公开(公告)日：2004-07-08
申请号：PCT/US0325415
申请日：2003-08-12
申请人： DYNAVAX TECH CORP , VAN NEST GARY , TUCK STEPHEN
发明人： VAN NEST GARY , TUCK STEPHEN
IPC分类号： A61K9/00 , A61K9/56 , A61K9/60 , A61K9/66 , A61K31/00 , A61K39/39 , A61K45/06 , A61K47/10 , A61K47/26 , A61K47/42 , A01N37/18 , A01N43/04 , A61K9/127 , A61K9/14 , A61K31/70 , A61K38/00 , A61K38/16 , A61K39/00 , A61K39/12 , A61K39/38
CPC分类号： A61K9/0014 , A61K9/0019 , A61K9/0073 , A61K31/00 , A61K39/39 , A61K45/06 , A61K47/10 , A61K47/26 , A61K47/42 , A61K2039/55561 , A61K2300/00
摘要： The invention relates to new immunomodulatory compositions which comprise a cationic condensing agent, an immunomodulatory compound, and a stabilizing agent. The compositions of the invention typically form particles which have increased immunomodulatory activity as compared to immunomodulatory compounds not formulated in the compositions of the invention. Also provided are methods of making the compositions and methods for therapeutic use of the compositions.
摘要翻译：本发明涉及包含阳离子缩合剂，免疫调节化合物和稳定剂的新型免疫调节组合物。与未配制在本发明组合物中的免疫调节化合物相比，本发明的组合物通常形成免疫调节活性增加的颗粒。还提供了制备用于组合物治疗用途的组合物和方法的方法。

9. 发明申请

WO0226210A3 PROTON PUMP INHIBITOR FORMULATION 审中-公开
标题翻译：质子泵抑制剂制剂
公开(公告)号：WO0226210A3
公开(公告)日：2002-12-19
申请号：PCT/US0142298
申请日：2001-09-25
申请人： GENEVA PHARMACEUTICALS INC , CULLEN DAN , PELLONI CHRISTOPHER L
发明人： CULLEN DAN , PELLONI CHRISTOPHER L
IPC分类号： A61K9/16 , A61K9/48 , A61K9/50 , A61K9/54 , A61K9/56 , A61K31/4439 , A61K9/28
CPC分类号： A61K9/5026 , A61K9/1623 , A61K9/1652 , A61K9/4808
摘要： Pharmaceutical capsule dosage forms of benzimidazole proton pump inhibitors are prepared by enclosing one or several enteric coated compressed cores in a capsule shell. The inventive formulations are stable and have higher bioavailability of the active ingredient relative to pellet and granule containing formulations.
摘要翻译：苯并咪唑质子泵抑制剂的药物胶囊剂型通过将一个或多个肠溶包衣的压制芯包封在胶囊壳中来制备。本发明的制剂相对于含有颗粒和颗粒的制剂是稳定的并且具有更高的活性成分的生物利用度。

10. 发明申请

WO02034234A2 METHYLPHENIDATE MODIFIED RELEASE FORMULATIONS 审中-公开
标题翻译：甲基苯酚改性释放配方
公开(公告)号：WO02034234A2
公开(公告)日：2002-05-02
申请号：PCT/US2001/042561
申请日：2001-10-09
IPC分类号： A61K9/22 , A61K9/50 , A61K9/54 , A61K9/56 , A61K9/58 , A61K9/62 , A61K31/4458 , A61K47/14 , A61K47/26 , A61K47/30 , A61K47/32 , A61K47/36 , A61K47/38 , A61K9/00
CPC分类号： A61K31/4458 , A61K9/5078 , A61K9/5084
摘要： A pharmaceutical MR (modified release) multiparticulate dosage form such as a capsule (once-a-day MR Capsule) of Methylphenidate indicated for the treatment of children with attention deficit hyperactivity disorder (ADHD), capable of delivering a portion of the dose for rapid onset of action and the remainder of the dose in a controlled manner for about 12 hours, is composed of a multitude of multicoated particles made of two populations of drug layered beads, IR (immediate release) and ER (extended release) Beads. The IR beads preferably are made by layering an aqueous solution comprising a drug and a binder on to non-pareil sugar spheres and then applying a seal coat to the drug coated cores. The ER Beads are made by applying an extended release coating of a water insoluble dissolution rate controlling polymer such as ethylcellulose to IR Beads. The MR Capsules are manufactured by filling IR and ER Beads in a proper ratio; the dose and the ratio required for an efficacious, cost effective and patient compliant treatment of children with ADHD were determined from extensive clinical investigations and in vitro/in vivo correlations performed as per FDA Guidelines, Guidance for Industry: Extended Release Oral Dosage Forms.
摘要翻译：药物MR（改性释放）多颗粒剂型，例如哌甲酯的胶囊（每日一次MR胶囊），用于治疗注意缺陷多动障碍（ADHD）的儿童，能够递送一部分剂量用于快速起始作用和其他剂量以受控方式进行约12小时，由多个由多种药物分层珠，IR（即时释放）和ER（延长释放）珠组成的多层颗粒组成。 IR珠优选通过将包含药物和粘合剂的水溶液层压到非帕里儿糖球上，然后将涂层涂覆到药物包衣的核心上来制备。 ER珠是通过将不溶于水的溶解速率控制聚合物如乙基纤维素的延长释放涂层施加到IR珠而制成的。 MR胶囊通过以适当的比例填充IR和ER珠来制造; 根据FDA指南“行业指南”进行的广泛临床研究和体外/体内相关性测定了对ADHD儿童进行有效，成本效益和患者适应性治疗所需的剂量和比例。延长口服剂型。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式